Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-Intense Chemo with PBPC in Metastatic Breast Cancer
NCT00002837Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 1995
- Primary completion
- Jan 2002
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin, paclitaxel and cyclophosphamide in breast cancer, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Dose. Started Sep 1995; status: completed.
02
Drugs
doxorubicinpaclitaxelcyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00002837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002837.